

# One-step synthesis of 2-arylbenzothiazole ('BTA') and -benzoxazole precursors for in vivo imaging of $\beta$ -amyloid plaques

David Alagille,<sup>a</sup> Ronald M. Baldwin<sup>a</sup> and Gilles D. Tamagnan<sup>a,b,\*</sup>

<sup>a</sup>*Yale University and VA CT HCS, Department of Psychiatry, 333 Cedar Street, New Haven, CT 06510, USA*

<sup>b</sup>*Institute for Neurodegenerative Disorders, 60 Temple Street, Suite 8B, New Haven, CT 06510, USA*

Received 22 September 2004; accepted 21 December 2004

Available online 12 January 2005

**Abstract**—We report the simple and efficient synthesis of 2-arylbenzothiazoles ('BTA') and 2-arylbenzoxazoles by direct coupling of benzothiazoles or benzoxazoles with aryl bromides. This method permits direct one-step access to precursors of radiolabeled BTA-1 and BTA-2 and their 6-methoxy analogues, used for in vivo imaging of  $\beta$ -amyloid plaques with positron emission tomography (PET).

© 2004 Elsevier Ltd. All rights reserved.

Alzheimer's disease (AD) is a member of a heterogeneous family of diseases referred to as amyloidosis, including type II diabetes, variant Creutzfeldt-Jakob disease, painful joints associated with long-term hemodialysis, and rare cases of hereditary insomnia.<sup>1</sup> In all of these disorders, proteins that are normally soluble are converted into insoluble aggregates that can form intractable and frequently toxic deposits in skeletal muscular tissue and in organs such as heart, liver, and brain.<sup>2</sup> In vivo biomarkers of amyloid deposits in the brain would be useful to identify and follow individuals at risk for AD and to assist the evaluation of new anti-amyloid therapies under development.<sup>3,4</sup> A large number of radiolabeled compounds have been investigated as radioactive amyloid agents<sup>5–11</sup> for imaging amyloid plaque by positron emission tomography (PET). The 2-arylbenzothiazole (BTA) derivatives represent one of the most promising families.<sup>8,12</sup> The reported synthesis of 2-arylbenzothiazoles have commonly used one of two methods: condensation of *ortho*-amino thiophenols with substituted aldehydes, carboxylic acids, acyl chlorides, or nitriles;<sup>12</sup> or Jacobson's cyclization of thiobenzanilides mediated by potassium ferricyanide.<sup>12</sup> Yields from these methods are relatively low and the condensation method also has the limitation of a readily oxidiz-

able sulfur group. Recently, Majo et al.<sup>13</sup> reported Suzuki cross-coupling between 2-bromobenzothiazoles and boronic acids or esters however, the moderate to low yield and scarcity of commercially available boronic acids/esters limit the use of this reaction despite the remarkable advantage of a one-step synthesis. The same year, Yokooji et al.<sup>14</sup> reported the direct arylation of thiazoles with aryl bromides in the presence of Pd(OAc)<sub>2</sub>/P(*t*-Bu)<sub>3</sub> and they extended this reaction to a very small number of benzothiazoles. In this letter, we describe extending the potential application of the direct coupling between benzothiazole **1** or 6-methoxybenzothiazole **2** and aryl bromides with the objective of a one-step synthesis of precursors to radiotracers for imaging amyloid plaques in vivo.

Benzothiazole **1** or 6-methoxybenzothiazole **2** was reacted at 150 °C in a sealed tube with aryl bromide in DMF in the presence of Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, and CuBr with P(*t*-Bu)<sub>3</sub> as ligand<sup>19</sup> yielding after 1–3 h of reaction the desired 2-arylbenzothiazole in 66–84% yield (Table 1). In contrast with the Suzuki cross-coupling, this method permitted direct synthesis in good yield of 2-(2,4-dimethoxyphenyl)benzothiazole **5f** and its 6-methoxy analogue **5m**. This reaction allows us to obtain in good yield and in one-step (no protection of the nitrogen required) the BTA-1 and BTA-2 precursors (**5b** and **5c**) as well as their 6-methoxy analogues (**5h** and **5i**). Reaction of the 4-bromo-*N*-Boc protected aniline led to the deprotected compound by thermal cleavage of the *N*-Boc group as the major product. To conclude this work

**Keywords:** 2-Arylbenzothiazole; BTA; 2-Arylbenzoxazole; Amyloid plaques; Palladium; Direct coupling.

\*Corresponding author. Tel.: +1 2034014309; fax: +1 2037892119; e-mail: [gtamagnan@indd.org](mailto:gtamagnan@indd.org)

**Table 1.** Direct coupling of **1–3** with aryl bromides

$  \begin{array}{c}  \text{Y} \\    \\  \text{C}_6\text{H}_3\text{X} \\    \\  \text{N}=\text{CH}  \end{array}  + \text{Ar}-\text{Br}  \xrightarrow[\text{DMF, 150}^\circ\text{C, 1h}]{\text{Pd(OAc)}_2 / \text{P}(t\text{-Bu})_3, \text{Cs}_2\text{CO}_3 / \text{CuBr}}  \begin{array}{c}  \text{Y} \\    \\  \text{C}_6\text{H}_3\text{X} \\    \\  \text{N}=\text{CH}-\text{Ar}  \end{array}  $				
	$\begin{array}{l} \text{X} = \text{S}, \text{Y} = \text{H}, \quad \mathbf{1} \\ \text{X} = \text{S}, \text{Y} = \text{OMe} \quad \mathbf{2} \\ \text{X} = \text{O}, \text{Y} = \text{H}, \quad \mathbf{3} \end{array}$	<b>4a-f</b>	<b>5a-p</b>	
Benzazole	Aryl bromide	Product	Yield <sup>a</sup>	Suzuki yield <sup>b</sup>
<b>1</b>		<b>5a</b>	79	48
<b>1</b>		<b>5b<sup>c</sup></b>	68	—
<b>1</b>		<b>5c<sup>c</sup></b> BAT-1	71	—
<b>1</b>		<b>5d</b> BAT-2	78	—
<b>1</b>		<b>5b</b> (NH <sub>2</sub> ) <b>5e</b> (NHBoc)	63 8	—
<b>1</b>		<b>5f</b>	84	0
<b>2</b>		<b>5g</b>	71	54
<b>2</b>		<b>5h<sup>c</sup></b>	66	35
<b>2</b>		<b>5i<sup>c</sup></b> 6-OMe-BAT-1	78	—
<b>2</b>		<b>5j</b> 6-OMe-BAT-2	78	—
<b>2</b>		<b>5h</b> (NH <sub>2</sub> ) <b>5k</b> (NHBoc)	68 10	— 55
<b>2</b>		<b>5m</b>	77	—
<b>3</b>		<b>5n<sup>c</sup></b>	70	—
<b>3</b>		<b>5o</b>	72	—
<b>3</b>		<b>5p</b>	64	—

The reaction was carried out using Pd(OAc)<sub>2</sub>-P(*t*-Bu)<sub>3</sub> (0.05 and 0.1 equiv to benzothio- or benzoxazole), Cs<sub>2</sub>CO<sub>3</sub> (1 equiv) and CuBr (0.2 equiv) in DMF, sealed tube at 150 °C for 1 h unless otherwise noted.<sup>19</sup>

<sup>a</sup> Yield refers to pure isolated product.

<sup>b</sup> Previously published yield shown here for comparison.<sup>13</sup>

<sup>c</sup> Reaction time was extended to 3 h.

we investigated the possible application of this methodology to the synthesis of 2-arylbenzoxazoles, even though the synthesis of such compounds is well described in the literature by other synthetic means (oxidative cyclization of phenolic Schiff's bases<sup>15,16</sup> or coupling of 2-aminophenols with carboxylic acids<sup>17,18</sup>). In the

same manner as benzothiazole, benzoxazole **3** react with aryl bromide to provide after 1 h at 150 °C the desired 2-arylbenzoxazole (Table 1).

In summary, we report a simple and efficient synthesis of 2-arylbenzothiazoles and 2-arylbenzoxazoles using a

direct palladium-catalyzed arylation of benzothiazoles or benzoxazoles with aryl bromides. This methodology permits the direct synthesis of precursors to radiotracers for the imaging of amyloid deposit in vivo and allows the development of a large library of 2-aryl-benzothiazoles.

### Acknowledgements

This work was supported in part by the National Institutes of Health (DA16180-01) and from Department of Veterans Affairs, National Center for PTSD Alcohol Research.

### References and notes

- Selkoe, D. J. *Nature* **2003**, 426, 900.
- Rochet, J. C.; Lansbury, P. T., Jr. *Curr. Opin. Struct. Biol.* **2000**, 10, 60.
- Schenk, D. B.; Rydel, R. E.; May, P.; Little, S.; Panetta, J.; Lieberburg, I.; Sinha, S. *J. Med. Chem.* **1995**, 38, 4141.
- Holtzman, D. M.; Bales, K. R.; Paul, S. M.; DeMattos, R. B. *Adv. Drug Deliv. Rev.* **2002**, 54, 1603.
- Dezutter, N. A.; Dom, R. J.; de Groot, T. J.; Bormans, G. M.; Verbruggen, A. M. *Eur. J. Nucl. Med.* **1999**, 26, 1392.
- Klunk, W. E.; Bacskai, B. J.; Mathis, C. A.; Kajdasz, S. T.; McLellan, M. E.; Frosch, M. P.; Debnath, M. L.; Holt, D. P.; Wang, Y.; Hyman, B. T. *J. Neuropathol. Exp. Neurol.* **2002**, 61, 797.
- Klunk, W. E.; Wang, Y.; Huang, G.-F.; Debnath, M. L.; Holt, D. P.; Mathis, C. A. *Life Sci.* **2001**, 69, 1471.
- Mathis, C. A.; Bacskai, B. J.; Kajdasz, S. T.; McLellan, M. E.; Frosch, M. P.; Hyman, B. T.; Holt, D. P.; Wang, Y.; Huang, G.-F.; Debnath, M. L.; Klunk, W. E. *Bioorg. Med. Chem. Lett.* **2002**, 12, 295.
- Zhuang, Z.-P.; Kung, M.-P.; Hou, C.; Plossl, K.; Skovronsky, D.; Gur, T. L.; Trojanowski, J. Q.; Lee, V. M.-Y.; Kung, H. F. *Nuc. Med. Biol.* **2001**, 28, 887.
- Zhuang, Z. P.; Kung, M. P.; Wilson, A.; Lee, C. W.; Plossl, K.; Hou, C.; Holtzman, D. M.; Kung, H. F. *J. Med. Chem.* **2003**, 46, 237.
- Agdeppa, E. D.; Kepe, V.; Liu, J.; Flores-Torres, S.; Satyamurthy, N.; Petric, A.; Cole, G. M.; Small, G. W.; Huang, S. C.; Barrio, J. R. *J. Neurosci.* **2001**, 21, RC189/1.
- Mathis, C. A.; Wang, Y.; Holt, D. P.; Huang, G. F.; Debnath, M. L.; Klunk, W. E. *J. Med. Chem.* **2003**, 46, 2740.
- Majo, V. J.; Prabhakaran, J.; Mann, J. J.; Kumar, J. S. D. *Tetrahedron Lett.* **2003**, 44, 8535.
- Yokooji, A.; Okazawa, T.; Satoh, T.; Miura, M.; Nomura, M. *Tetrahedron Lett.* **2003**, 59, 5685.
- Chang, J.; Zhao, K.; Pan, S. *Tetrahedron Lett.* **2002**, 43, 951.
- Varma, R. S.; Saini, R. K.; Prakash, O. *Tetrahedron Lett.* **1997**, 38, 2621.
- Bougrin, K.; Loupy, A.; Soufiaoui, M. *Tetrahedron* **1998**, 54, 8055.
- Terashima, M.; Ishii, M.; Kanaoka, Y. *Synthesis* **1982**, 6, 484.
- Typical experimental procedure: A suspension of benzothiazole or benzoxazole (1.21 mmol, 1 equiv), aryl bromide (1.45 mmol, 1.2 equiv), dry Cs<sub>2</sub>CO<sub>3</sub> (1.21 mmol, 1 equiv), CuBr (0.24 mmol, 0.2 equiv), Pd(OAc)<sub>2</sub> (0.06 mmol, 0.05 equiv) and P(*t*-Bu)<sub>3</sub> (0.12 mmol, 0.1 equiv) in DMF (10 mL) was heated under argon with stirring in a sealed tube at 150 °C for 1–3 h (Table 1). After cooling, the reaction mixture was diluted with EtOAc and washed several times with H<sub>2</sub>O, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum, and flash column chromatographed (silica gel/hexane:EtOAc, 98:2 to 80:20 or CH<sub>2</sub>Cl<sub>2</sub>/hexane/EtOAc, 5:4:1).